Business Context and Reporting Period
This Form 8-K was filed by AntriaBio, Inc. (not Rezolute, Inc.) on March 6, 2017. The report details the completion of the first closing of a Private Investment in Public Equity (PIPE) financing transaction.
Key Financial Metrics
- Transaction Type: Private placement of Common Stock.
- Shares Issued: 4,500,000 shares.
- Price Per Share: $1.00.
- Gross Proceeds: $4.5 million (excluding transaction costs, fees, and expenses).
- Total Target Raise: $15 million (subject to subsequent closings).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the issuance of 4.5 million shares to investors in the Republic of Korea and the United States. This represents the initial tranche of a planned larger financing round.
Guidance, Outlook, and Risks
- Outlook: The Company plans to conduct one or more subsequent closings on the same terms to reach a total raise of $15 million. No assurance is given that the Company will be successful in these efforts.
- Registration Rights: The Company agreed to file a registration statement within 30 days of the final close of the PIPE Financing to allow investors to resell shares.
- Risks/Contingencies: The securities were sold under Section 4(a)(2) and Rule 506 of Regulation D. They are not registered and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the identity of the investors in the Republic of Korea and the United States.
- Monitor the filing of the Registration Statement within the 30-day window following the final close.
- Track the progress of subsequent closings to determine if the full $15 million target is achieved.
- Review the attached Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.